Bristol Myers Squibb & Co (NYSE: BMY) announced updated results from a TRIDENT-1 study, demonstrating that repotrectinib — a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) — continued to show high response rates and durable responses in patients with
Performance Food Group Co (NYSE: PFGC) reported Q4 FY23 sales growth of 1.9% Y/Y to $14.87 billion, missing the consensus of $15.07 billion.
Net sales benefitted from a positive channel mix, higher cases sold, and increased selling price per case due to inflation.
Progressive Corp (NYSE: PGR) shares are trading higher by around 9% after the company reported July 2023 results.
The company issued monthly results today, reporting an increase in net premiums written to 21% to $5.95 billion in July.